Goldman Sachs
PCVX icon

Goldman Sachs’s Vaxcyte PCVX Stock Holding History

Goldman Sachs’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,000
Closed -$793K – 6334
2025
Q1 		$793K Buy
+21,000
New +$1.68M ﹤0.01% 4860

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Goldman Sachs's PCVX Position: Q2 2026 in Review

Goldman Sachs increased its Vaxcyte (PCVX) stake by 5.9% in Q2 2026, buying an estimated $4.11M and bringing the position to 1,350,760 shares worth $78.5M. The position accounts for 0.01% of the portfolio, ranked #1418.

Goldman Sachs first reported a position in PCVX in Q2 2020 and has held it in 24 quarters since. The position peaked at $256M in Q4 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Goldman Sachs held 1,350,760 shares of Vaxcyte worth $78.5M as of Q2 2026.
  • Goldman Sachs bought 75,724 Vaxcyte shares in Q2 2026, an estimated $4.11M.
  • Vaxcyte made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1418 holding.
  • Goldman Sachs first reported a position in Vaxcyte in Q2 2020 and has held it in 24 quarters since.
  • Goldman Sachs's Vaxcyte position peaked at $256M in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.